Categories
Life Sciences Consumer Goods Materials and Chemicals Construction & Manufacturing Food and Beverages Energy and Power Semiconductor and Electronics Automotive and Transportation ICT & Media Aerospace & Defense BFSI

Int'l : +1-503-894-6022 | Toll Free : +1-800-792-5285 | help@alliedmarketresearch.com

Surgical Hemostats Market by Product Type (Gelatin Based, Combination Hemostats, Cellulose Based, Oxidized Regenerated, Collagen Based) and by End Users (Hospitals, Ambulatory Surgical Centers, Specialty Clinics): Global Opportunity Analysis and Industry Forecast, 2023-2032

A03329

Pages: NA

Charts: NA

Tables: NA

During surgeries, blood loss occurs due to the disruption of blood vessels. It is important to coagulate the blood to avoid too much blood loss. The formation of blood clots at the site of injury is called hemostasis. Hemostats are surgical tools that are utilized during surgeries to control the bleeding of the patient. These tools help to temporarily form blood clots to control bleeding. However, it is important that the use of these tools is localized and carefully regulated.

The rise in the incidence of various diseases and increase in concern & awareness about health are the major driving factors for the growth of the surgical hemostats market. Moreover, advancements in technology along with an increase in funding in R&D boost the market growth. In addition, an increase in the number of surgeries will further fuel the market growth. However, advancements in minimally invasive surgical procedures will reduce the use of surgical hemostat and thus hamper the market growth.

The global surgical hemostats market is segmented based on product type, end users, and geography. Based on product type, the market is segmented into oxidized regenerated, gelatin based, cellulose based, combination hemostats, and collagen based. Based on end users, the market is categorized into hospitals, ambulatory surgical centers, and specialty clinics. Based on geography, the market has been examined across North America, Europe, Asia-Pacific, and LAMEA.

Comprehensive competitive analysis and profiles of major market players such as CSL Behring, Johnson & Johnson, Marine Polymer Technologies, Inc., CryoLife, Inc., C. R. Bard, Inc., Z-Medica, LLC, Baxter, Pfizer Inc., Integra Lifesciences Holdings Corporation, B Braun Melsungen AG, and Vascular Solutions, Inc. have also been provided in this report.

Key Benefits

  • This report provides an extensive analysis of the current and emerging market trends and dynamics in the global market.
  • This report entails a detailed quantitative analysis of the current market and estimations, which assists in identifying prevailing market opportunities.
  • The projections in this report are made by analyzing the current trends and future market potential in terms of value.
  • Competitive intelligence helps understand the competitive scenario globally.
  • An in-depth analysis of current research and clinical developments within the market has been provided with key market dynamic factors that help understand the behavior of the market.

 Key Market Segments

  • By Product Type
    • Gelatin Based
    • Combination Hemostats
    • Cellulose Based
    • Oxidized Regenerated
    • Collagen Based
  • By End Users
    • Hospitals
    • Ambulatory Surgical Centers
    • Specialty Clinics
  • By Region
    • North America
      • U.S.
      • Canada
      • Mexico
    • Europe
      • France
      • Germany
      • Italy
      • Spain
      • UK
      • Rest of Europe
    • Asia-Pacific
      • China
      • Japan
      • India
      • South Korea
      • Australia
      • Rest of Asia-Pacific
    • LAMEA
      • Brazil
      • South Africa
      • Saudi Arabia
      • Rest of LAMEA

 
Key Market Players

  • Johnson & Johnson
  • CryoLife, Inc.
  • Integra Lifesciences Holdings Corporation
  • C. R. Bard, Inc.
  • CSL Behring
  • Marine Polymer Technologies, Inc.
  • B Braun Melsungen AG
  • Baxter, Pfizer Inc.
  • Z-Medica, LLC
  • Vascular Solutions, Inc.

  • CHAPTER 1: INTRODUCTION

    • 1.1. Report Description

    • 1.2. Key Market Segments

    • 1.3. Key Benefits

    • 1.4. Research Methodology

      • 1.4.1. Primary Research

      • 1.4.2. Secondary Research

      • 1.4.3. Analyst Tools and Models

  • CHAPTER 2: EXECUTIVE SUMMARY

    • 2.1. CXO Perspective

  • CHAPTER 3: MARKET LANDSCAPE

    • 3.1. Market Definition and Scope

    • 3.2. Key Findings

      • 3.2.1. Top Investment Pockets

      • 3.2.2. Top Winning Strategies

    • 3.3. Porter's Five Forces Analysis

      • 3.3.1. Bargaining Power of Suppliers

      • 3.3.2. Threat of New Entrants

      • 3.3.3. Threat of Substitutes

      • 3.3.4. Competitive Rivalry

      • 3.3.5. Bargaining Power among Buyers

    • 3.5. Market Dynamics

      • 3.5.1. Drivers

      • 3.5.2. Restraints

      • 3.5.3. Opportunities

  • CHAPTER 4: SURGICAL HEMOSTATS MARKET, BY PRODUCT TYPE

    • 4.1. Market Overview

      • 4.1.1 Market Size and Forecast, By Product Type

    • 4.2. Gelatin Based

      • 4.2.1. Key Market Trends, Growth Factors and Opportunities

      • 4.2.2. Market Size and Forecast, By Region

      • 4.2.3. Market Share Analysis, By Country

    • 4.3. Combination Hemostats

      • 4.3.1. Key Market Trends, Growth Factors and Opportunities

      • 4.3.2. Market Size and Forecast, By Region

      • 4.3.3. Market Share Analysis, By Country

    • 4.4. Cellulose Based

      • 4.4.1. Key Market Trends, Growth Factors and Opportunities

      • 4.4.2. Market Size and Forecast, By Region

      • 4.4.3. Market Share Analysis, By Country

    • 4.5. Oxidized Regenerated

      • 4.5.1. Key Market Trends, Growth Factors and Opportunities

      • 4.5.2. Market Size and Forecast, By Region

      • 4.5.3. Market Share Analysis, By Country

    • 4.6. Collagen Based

      • 4.6.1. Key Market Trends, Growth Factors and Opportunities

      • 4.6.2. Market Size and Forecast, By Region

      • 4.6.3. Market Share Analysis, By Country

  • CHAPTER 5: SURGICAL HEMOSTATS MARKET, BY END USERS

    • 5.1. Market Overview

      • 5.1.1 Market Size and Forecast, By End Users

    • 5.2. Hospitals

      • 5.2.1. Key Market Trends, Growth Factors and Opportunities

      • 5.2.2. Market Size and Forecast, By Region

      • 5.2.3. Market Share Analysis, By Country

    • 5.3. Ambulatory Surgical Centers

      • 5.3.1. Key Market Trends, Growth Factors and Opportunities

      • 5.3.2. Market Size and Forecast, By Region

      • 5.3.3. Market Share Analysis, By Country

    • 5.4. Specialty Clinics

      • 5.4.1. Key Market Trends, Growth Factors and Opportunities

      • 5.4.2. Market Size and Forecast, By Region

      • 5.4.3. Market Share Analysis, By Country

  • CHAPTER 6: SURGICAL HEMOSTATS MARKET, BY REGION

    • 6.1. Market Overview

      • 6.1.1 Market Size and Forecast, By Region

    • 6.2. North America

      • 6.2.1. Key Market Trends and Opportunities

      • 6.2.2. Market Size and Forecast, By Product Type

      • 6.2.3. Market Size and Forecast, By End Users

      • 6.2.4. Market Size and Forecast, By Country

      • 6.2.5. U.S. Surgical Hemostats Market

        • 6.2.5.1. Market Size and Forecast, By Product Type
        • 6.2.5.2. Market Size and Forecast, By End Users

      • 6.2.6. Canada Surgical Hemostats Market

        • 6.2.6.1. Market Size and Forecast, By Product Type
        • 6.2.6.2. Market Size and Forecast, By End Users

      • 6.2.7. Mexico Surgical Hemostats Market

        • 6.2.7.1. Market Size and Forecast, By Product Type
        • 6.2.7.2. Market Size and Forecast, By End Users

    • 6.3. Europe

      • 6.3.1. Key Market Trends and Opportunities

      • 6.3.2. Market Size and Forecast, By Product Type

      • 6.3.3. Market Size and Forecast, By End Users

      • 6.3.4. Market Size and Forecast, By Country

      • 6.3.5. France Surgical Hemostats Market

        • 6.3.5.1. Market Size and Forecast, By Product Type
        • 6.3.5.2. Market Size and Forecast, By End Users

      • 6.3.6. Germany Surgical Hemostats Market

        • 6.3.6.1. Market Size and Forecast, By Product Type
        • 6.3.6.2. Market Size and Forecast, By End Users

      • 6.3.7. Italy Surgical Hemostats Market

        • 6.3.7.1. Market Size and Forecast, By Product Type
        • 6.3.7.2. Market Size and Forecast, By End Users

      • 6.3.8. Spain Surgical Hemostats Market

        • 6.3.8.1. Market Size and Forecast, By Product Type
        • 6.3.8.2. Market Size and Forecast, By End Users

      • 6.3.9. UK Surgical Hemostats Market

        • 6.3.9.1. Market Size and Forecast, By Product Type
        • 6.3.9.2. Market Size and Forecast, By End Users

      • 6.3.10. Russia Surgical Hemostats Market

        • 6.3.10.1. Market Size and Forecast, By Product Type
        • 6.3.10.2. Market Size and Forecast, By End Users

      • 6.3.11. Rest Of Europe Surgical Hemostats Market

        • 6.3.11.1. Market Size and Forecast, By Product Type
        • 6.3.11.2. Market Size and Forecast, By End Users

    • 6.4. Asia-Pacific

      • 6.4.1. Key Market Trends and Opportunities

      • 6.4.2. Market Size and Forecast, By Product Type

      • 6.4.3. Market Size and Forecast, By End Users

      • 6.4.4. Market Size and Forecast, By Country

      • 6.4.5. China Surgical Hemostats Market

        • 6.4.5.1. Market Size and Forecast, By Product Type
        • 6.4.5.2. Market Size and Forecast, By End Users

      • 6.4.6. Japan Surgical Hemostats Market

        • 6.4.6.1. Market Size and Forecast, By Product Type
        • 6.4.6.2. Market Size and Forecast, By End Users

      • 6.4.7. India Surgical Hemostats Market

        • 6.4.7.1. Market Size and Forecast, By Product Type
        • 6.4.7.2. Market Size and Forecast, By End Users

      • 6.4.8. South Korea Surgical Hemostats Market

        • 6.4.8.1. Market Size and Forecast, By Product Type
        • 6.4.8.2. Market Size and Forecast, By End Users

      • 6.4.9. Australia Surgical Hemostats Market

        • 6.4.9.1. Market Size and Forecast, By Product Type
        • 6.4.9.2. Market Size and Forecast, By End Users

      • 6.4.10. Thailand Surgical Hemostats Market

        • 6.4.10.1. Market Size and Forecast, By Product Type
        • 6.4.10.2. Market Size and Forecast, By End Users

      • 6.4.11. Malaysia Surgical Hemostats Market

        • 6.4.11.1. Market Size and Forecast, By Product Type
        • 6.4.11.2. Market Size and Forecast, By End Users

      • 6.4.12. Indonesia Surgical Hemostats Market

        • 6.4.12.1. Market Size and Forecast, By Product Type
        • 6.4.12.2. Market Size and Forecast, By End Users

      • 6.4.13. Rest of Asia Pacific Surgical Hemostats Market

        • 6.4.13.1. Market Size and Forecast, By Product Type
        • 6.4.13.2. Market Size and Forecast, By End Users

    • 6.5. LAMEA

      • 6.5.1. Key Market Trends and Opportunities

      • 6.5.2. Market Size and Forecast, By Product Type

      • 6.5.3. Market Size and Forecast, By End Users

      • 6.5.4. Market Size and Forecast, By Country

      • 6.5.5. Brazil Surgical Hemostats Market

        • 6.5.5.1. Market Size and Forecast, By Product Type
        • 6.5.5.2. Market Size and Forecast, By End Users

      • 6.5.6. South Africa Surgical Hemostats Market

        • 6.5.6.1. Market Size and Forecast, By Product Type
        • 6.5.6.2. Market Size and Forecast, By End Users

      • 6.5.7. Saudi Arabia Surgical Hemostats Market

        • 6.5.7.1. Market Size and Forecast, By Product Type
        • 6.5.7.2. Market Size and Forecast, By End Users

      • 6.5.8. UAE Surgical Hemostats Market

        • 6.5.8.1. Market Size and Forecast, By Product Type
        • 6.5.8.2. Market Size and Forecast, By End Users

      • 6.5.9. Argentina Surgical Hemostats Market

        • 6.5.9.1. Market Size and Forecast, By Product Type
        • 6.5.9.2. Market Size and Forecast, By End Users

      • 6.5.10. Rest of LAMEA Surgical Hemostats Market

        • 6.5.10.1. Market Size and Forecast, By Product Type
        • 6.5.10.2. Market Size and Forecast, By End Users

  • CHAPTER 7: COMPETITIVE LANDSCAPE

    • 7.1. Introduction

    • 7.2. Top Winning Strategies

    • 7.3. Product Mapping Of Top 10 Player

    • 7.4. Competitive Dashboard

    • 7.5. Competitive Heatmap

    • 7.6. Top Player Positioning, 2024

  • CHAPTER 8: COMPANY PROFILES

    • 8.1. CSL Behring

      • 8.1.1. Company Overview

      • 8.1.2. Key Executives

      • 8.1.3. Company Snapshot

      • 8.1.4. Operating Business Segments

      • 8.1.5. Product Portfolio

      • 8.1.6. Business Performance

      • 8.1.7. Key Strategic Moves and Developments

    • 8.2. Johnson And Johnson

      • 8.2.1. Company Overview

      • 8.2.2. Key Executives

      • 8.2.3. Company Snapshot

      • 8.2.4. Operating Business Segments

      • 8.2.5. Product Portfolio

      • 8.2.6. Business Performance

      • 8.2.7. Key Strategic Moves and Developments

    • 8.3. Marine Polymer Technologies, Inc.

      • 8.3.1. Company Overview

      • 8.3.2. Key Executives

      • 8.3.3. Company Snapshot

      • 8.3.4. Operating Business Segments

      • 8.3.5. Product Portfolio

      • 8.3.6. Business Performance

      • 8.3.7. Key Strategic Moves and Developments

    • 8.4. CryoLife, Inc.

      • 8.4.1. Company Overview

      • 8.4.2. Key Executives

      • 8.4.3. Company Snapshot

      • 8.4.4. Operating Business Segments

      • 8.4.5. Product Portfolio

      • 8.4.6. Business Performance

      • 8.4.7. Key Strategic Moves and Developments

    • 8.5. C. R. Bard, Inc.

      • 8.5.1. Company Overview

      • 8.5.2. Key Executives

      • 8.5.3. Company Snapshot

      • 8.5.4. Operating Business Segments

      • 8.5.5. Product Portfolio

      • 8.5.6. Business Performance

      • 8.5.7. Key Strategic Moves and Developments

    • 8.6. Z-Medica, LLC

      • 8.6.1. Company Overview

      • 8.6.2. Key Executives

      • 8.6.3. Company Snapshot

      • 8.6.4. Operating Business Segments

      • 8.6.5. Product Portfolio

      • 8.6.6. Business Performance

      • 8.6.7. Key Strategic Moves and Developments

    • 8.7. Baxter, Pfizer Inc.

      • 8.7.1. Company Overview

      • 8.7.2. Key Executives

      • 8.7.3. Company Snapshot

      • 8.7.4. Operating Business Segments

      • 8.7.5. Product Portfolio

      • 8.7.6. Business Performance

      • 8.7.7. Key Strategic Moves and Developments

    • 8.8. Integra Lifesciences Holdings Corporation

      • 8.8.1. Company Overview

      • 8.8.2. Key Executives

      • 8.8.3. Company Snapshot

      • 8.8.4. Operating Business Segments

      • 8.8.5. Product Portfolio

      • 8.8.6. Business Performance

      • 8.8.7. Key Strategic Moves and Developments

    • 8.9. B Braun Melsungen AG

      • 8.9.1. Company Overview

      • 8.9.2. Key Executives

      • 8.9.3. Company Snapshot

      • 8.9.4. Operating Business Segments

      • 8.9.5. Product Portfolio

      • 8.9.6. Business Performance

      • 8.9.7. Key Strategic Moves and Developments

    • 8.10. Vascular Solutions, Inc.

      • 8.10.1. Company Overview

      • 8.10.2. Key Executives

      • 8.10.3. Company Snapshot

      • 8.10.4. Operating Business Segments

      • 8.10.5. Product Portfolio

      • 8.10.6. Business Performance

      • 8.10.7. Key Strategic Moves and Developments

  • LIST OF TABLES

  • TABLE 1. GLOBAL SURGICAL HEMOSTATS MARKET, BY PRODUCT TYPE, 2025-2033 ($MILLION)
  • TABLE 2. GLOBAL SURGICAL HEMOSTATS MARKET FOR GELATIN BASED, BY REGION, 2025-2033 ($MILLION)
  • TABLE 3. GLOBAL SURGICAL HEMOSTATS MARKET FOR COMBINATION HEMOSTATS, BY REGION, 2025-2033 ($MILLION)
  • TABLE 4. GLOBAL SURGICAL HEMOSTATS MARKET FOR CELLULOSE BASED, BY REGION, 2025-2033 ($MILLION)
  • TABLE 5. GLOBAL SURGICAL HEMOSTATS MARKET FOR OXIDIZED REGENERATED, BY REGION, 2025-2033 ($MILLION)
  • TABLE 6. GLOBAL SURGICAL HEMOSTATS MARKET FOR COLLAGEN BASED, BY REGION, 2025-2033 ($MILLION)
  • TABLE 7. GLOBAL SURGICAL HEMOSTATS MARKET, BY END USERS, 2025-2033 ($MILLION)
  • TABLE 8. GLOBAL SURGICAL HEMOSTATS MARKET FOR HOSPITALS, BY REGION, 2025-2033 ($MILLION)
  • TABLE 9. GLOBAL SURGICAL HEMOSTATS MARKET FOR AMBULATORY SURGICAL CENTERS, BY REGION, 2025-2033 ($MILLION)
  • TABLE 10. GLOBAL SURGICAL HEMOSTATS MARKET FOR SPECIALTY CLINICS, BY REGION, 2025-2033 ($MILLION)
  • TABLE 11. GLOBAL SURGICAL HEMOSTATS MARKET, BY REGION, 2025-2033 ($MILLION)
  • TABLE 12. NORTH AMERICA SURGICAL HEMOSTATS, BY REGION, 2025-2033 ($MILLION)
  • TABLE 13. NORTH AMERICA SURGICAL HEMOSTATS, BY PRODUCT TYPE, 2025-2033 ($MILLION)
  • TABLE 14. NORTH AMERICA SURGICAL HEMOSTATS, BY END USERS, 2025-2033 ($MILLION)
  • TABLE 15. U.S. SURGICAL HEMOSTATS, BY PRODUCT TYPE, 2025-2033 ($MILLION)
  • TABLE 16. U.S. SURGICAL HEMOSTATS, BY END USERS, 2025-2033 ($MILLION)
  • TABLE 17. CANADA SURGICAL HEMOSTATS, BY PRODUCT TYPE, 2025-2033 ($MILLION)
  • TABLE 18. CANADA SURGICAL HEMOSTATS, BY END USERS, 2025-2033 ($MILLION)
  • TABLE 19. MEXICO SURGICAL HEMOSTATS, BY PRODUCT TYPE, 2025-2033 ($MILLION)
  • TABLE 20. MEXICO SURGICAL HEMOSTATS, BY END USERS, 2025-2033 ($MILLION)
  • TABLE 21. EUROPE SURGICAL HEMOSTATS, BY REGION, 2025-2033 ($MILLION)
  • TABLE 22. EUROPE SURGICAL HEMOSTATS, BY PRODUCT TYPE, 2025-2033 ($MILLION)
  • TABLE 23. EUROPE SURGICAL HEMOSTATS, BY END USERS, 2025-2033 ($MILLION)
  • TABLE 24. FRANCE SURGICAL HEMOSTATS, BY PRODUCT TYPE, 2025-2033 ($MILLION)
  • TABLE 25. FRANCE SURGICAL HEMOSTATS, BY END USERS, 2025-2033 ($MILLION)
  • TABLE 26. GERMANY SURGICAL HEMOSTATS, BY PRODUCT TYPE, 2025-2033 ($MILLION)
  • TABLE 27. GERMANY SURGICAL HEMOSTATS, BY END USERS, 2025-2033 ($MILLION)
  • TABLE 28. ITALY SURGICAL HEMOSTATS, BY PRODUCT TYPE, 2025-2033 ($MILLION)
  • TABLE 29. ITALY SURGICAL HEMOSTATS, BY END USERS, 2025-2033 ($MILLION)
  • TABLE 30. SPAIN SURGICAL HEMOSTATS, BY PRODUCT TYPE, 2025-2033 ($MILLION)
  • TABLE 31. SPAIN SURGICAL HEMOSTATS, BY END USERS, 2025-2033 ($MILLION)
  • TABLE 32. UK SURGICAL HEMOSTATS, BY PRODUCT TYPE, 2025-2033 ($MILLION)
  • TABLE 33. UK SURGICAL HEMOSTATS, BY END USERS, 2025-2033 ($MILLION)
  • TABLE 34. RUSSIA SURGICAL HEMOSTATS, BY PRODUCT TYPE, 2025-2033 ($MILLION)
  • TABLE 35. RUSSIA SURGICAL HEMOSTATS, BY END USERS, 2025-2033 ($MILLION)
  • TABLE 36. REST OF EUROPE SURGICAL HEMOSTATS, BY PRODUCT TYPE, 2025-2033 ($MILLION)
  • TABLE 37. REST OF EUROPE SURGICAL HEMOSTATS, BY END USERS, 2025-2033 ($MILLION)
  • TABLE 38. ASIA-PACIFIC SURGICAL HEMOSTATS, BY REGION, 2025-2033 ($MILLION)
  • TABLE 39. ASIA-PACIFIC SURGICAL HEMOSTATS, BY PRODUCT TYPE, 2025-2033 ($MILLION)
  • TABLE 40. ASIA-PACIFIC SURGICAL HEMOSTATS, BY END USERS, 2025-2033 ($MILLION)
  • TABLE 41. CHINA SURGICAL HEMOSTATS, BY PRODUCT TYPE, 2025-2033 ($MILLION)
  • TABLE 42. CHINA SURGICAL HEMOSTATS, BY END USERS, 2025-2033 ($MILLION)
  • TABLE 43. JAPAN SURGICAL HEMOSTATS, BY PRODUCT TYPE, 2025-2033 ($MILLION)
  • TABLE 44. JAPAN SURGICAL HEMOSTATS, BY END USERS, 2025-2033 ($MILLION)
  • TABLE 45. INDIA SURGICAL HEMOSTATS, BY PRODUCT TYPE, 2025-2033 ($MILLION)
  • TABLE 46. INDIA SURGICAL HEMOSTATS, BY END USERS, 2025-2033 ($MILLION)
  • TABLE 47. SOUTH KOREA SURGICAL HEMOSTATS, BY PRODUCT TYPE, 2025-2033 ($MILLION)
  • TABLE 48. SOUTH KOREA SURGICAL HEMOSTATS, BY END USERS, 2025-2033 ($MILLION)
  • TABLE 49. AUSTRALIA SURGICAL HEMOSTATS, BY PRODUCT TYPE, 2025-2033 ($MILLION)
  • TABLE 50. AUSTRALIA SURGICAL HEMOSTATS, BY END USERS, 2025-2033 ($MILLION)
  • TABLE 51. THAILAND SURGICAL HEMOSTATS, BY PRODUCT TYPE, 2025-2033 ($MILLION)
  • TABLE 52. THAILAND SURGICAL HEMOSTATS, BY END USERS, 2025-2033 ($MILLION)
  • TABLE 53. MALAYSIA SURGICAL HEMOSTATS, BY PRODUCT TYPE, 2025-2033 ($MILLION)
  • TABLE 54. MALAYSIA SURGICAL HEMOSTATS, BY END USERS, 2025-2033 ($MILLION)
  • TABLE 55. INDONESIA SURGICAL HEMOSTATS, BY PRODUCT TYPE, 2025-2033 ($MILLION)
  • TABLE 56. INDONESIA SURGICAL HEMOSTATS, BY END USERS, 2025-2033 ($MILLION)
  • TABLE 57. REST OF ASIA PACIFIC SURGICAL HEMOSTATS, BY PRODUCT TYPE, 2025-2033 ($MILLION)
  • TABLE 58. REST OF ASIA PACIFIC SURGICAL HEMOSTATS, BY END USERS, 2025-2033 ($MILLION)
  • TABLE 59. LAMEA SURGICAL HEMOSTATS, BY REGION, 2025-2033 ($MILLION)
  • TABLE 60. LAMEA SURGICAL HEMOSTATS, BY PRODUCT TYPE, 2025-2033 ($MILLION)
  • TABLE 61. LAMEA SURGICAL HEMOSTATS, BY END USERS, 2025-2033 ($MILLION)
  • TABLE 62. BRAZIL SURGICAL HEMOSTATS, BY PRODUCT TYPE, 2025-2033 ($MILLION)
  • TABLE 63. BRAZIL SURGICAL HEMOSTATS, BY END USERS, 2025-2033 ($MILLION)
  • TABLE 64. SOUTH AFRICA SURGICAL HEMOSTATS, BY PRODUCT TYPE, 2025-2033 ($MILLION)
  • TABLE 65. SOUTH AFRICA SURGICAL HEMOSTATS, BY END USERS, 2025-2033 ($MILLION)
  • TABLE 66. SAUDI ARABIA SURGICAL HEMOSTATS, BY PRODUCT TYPE, 2025-2033 ($MILLION)
  • TABLE 67. SAUDI ARABIA SURGICAL HEMOSTATS, BY END USERS, 2025-2033 ($MILLION)
  • TABLE 68. UAE SURGICAL HEMOSTATS, BY PRODUCT TYPE, 2025-2033 ($MILLION)
  • TABLE 69. UAE SURGICAL HEMOSTATS, BY END USERS, 2025-2033 ($MILLION)
  • TABLE 70. ARGENTINA SURGICAL HEMOSTATS, BY PRODUCT TYPE, 2025-2033 ($MILLION)
  • TABLE 71. ARGENTINA SURGICAL HEMOSTATS, BY END USERS, 2025-2033 ($MILLION)
  • TABLE 72. REST OF LAMEA SURGICAL HEMOSTATS, BY PRODUCT TYPE, 2025-2033 ($MILLION)
  • TABLE 73. REST OF LAMEA SURGICAL HEMOSTATS, BY END USERS, 2025-2033 ($MILLION)
  • TABLE 74. CSL BEHRING: KEY EXECUTIVES
  • TABLE 75. CSL BEHRING: COMPANY SNAPSHOT
  • TABLE 76. CSL BEHRING: OPERATING SEGMENTS
  • TABLE 77. CSL BEHRING: PRODUCT PORTFOLIO
  • TABLE 78. CSL BEHRING: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 79. JOHNSON AND JOHNSON: KEY EXECUTIVES
  • TABLE 80. JOHNSON AND JOHNSON: COMPANY SNAPSHOT
  • TABLE 81. JOHNSON AND JOHNSON: OPERATING SEGMENTS
  • TABLE 82. JOHNSON AND JOHNSON: PRODUCT PORTFOLIO
  • TABLE 83. JOHNSON AND JOHNSON: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 84. MARINE POLYMER TECHNOLOGIES, INC.: KEY EXECUTIVES
  • TABLE 85. MARINE POLYMER TECHNOLOGIES, INC.: COMPANY SNAPSHOT
  • TABLE 86. MARINE POLYMER TECHNOLOGIES, INC.: OPERATING SEGMENTS
  • TABLE 87. MARINE POLYMER TECHNOLOGIES, INC.: PRODUCT PORTFOLIO
  • TABLE 88. MARINE POLYMER TECHNOLOGIES, INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 89. CRYOLIFE, INC.: KEY EXECUTIVES
  • TABLE 90. CRYOLIFE, INC.: COMPANY SNAPSHOT
  • TABLE 91. CRYOLIFE, INC.: OPERATING SEGMENTS
  • TABLE 92. CRYOLIFE, INC.: PRODUCT PORTFOLIO
  • TABLE 93. CRYOLIFE, INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 94. C. R. BARD, INC.: KEY EXECUTIVES
  • TABLE 95. C. R. BARD, INC.: COMPANY SNAPSHOT
  • TABLE 96. C. R. BARD, INC.: OPERATING SEGMENTS
  • TABLE 97. C. R. BARD, INC.: PRODUCT PORTFOLIO
  • TABLE 98. C. R. BARD, INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 99. Z-MEDICA, LLC: KEY EXECUTIVES
  • TABLE 100. Z-MEDICA, LLC: COMPANY SNAPSHOT
  • TABLE 101. Z-MEDICA, LLC: OPERATING SEGMENTS
  • TABLE 102. Z-MEDICA, LLC: PRODUCT PORTFOLIO
  • TABLE 103. Z-MEDICA, LLC: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 104. BAXTER, PFIZER INC.: KEY EXECUTIVES
  • TABLE 105. BAXTER, PFIZER INC.: COMPANY SNAPSHOT
  • TABLE 106. BAXTER, PFIZER INC.: OPERATING SEGMENTS
  • TABLE 107. BAXTER, PFIZER INC.: PRODUCT PORTFOLIO
  • TABLE 108. BAXTER, PFIZER INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 109. INTEGRA LIFESCIENCES HOLDINGS CORPORATION: KEY EXECUTIVES
  • TABLE 110. INTEGRA LIFESCIENCES HOLDINGS CORPORATION: COMPANY SNAPSHOT
  • TABLE 111. INTEGRA LIFESCIENCES HOLDINGS CORPORATION: OPERATING SEGMENTS
  • TABLE 112. INTEGRA LIFESCIENCES HOLDINGS CORPORATION: PRODUCT PORTFOLIO
  • TABLE 113. INTEGRA LIFESCIENCES HOLDINGS CORPORATION: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 114. B BRAUN MELSUNGEN AG: KEY EXECUTIVES
  • TABLE 115. B BRAUN MELSUNGEN AG: COMPANY SNAPSHOT
  • TABLE 116. B BRAUN MELSUNGEN AG: OPERATING SEGMENTS
  • TABLE 117. B BRAUN MELSUNGEN AG: PRODUCT PORTFOLIO
  • TABLE 118. B BRAUN MELSUNGEN AG: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 119. VASCULAR SOLUTIONS, INC.: KEY EXECUTIVES
  • TABLE 120. VASCULAR SOLUTIONS, INC.: COMPANY SNAPSHOT
  • TABLE 121. VASCULAR SOLUTIONS, INC.: OPERATING SEGMENTS
  • TABLE 122. VASCULAR SOLUTIONS, INC.: PRODUCT PORTFOLIO
  • TABLE 123. VASCULAR SOLUTIONS, INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS

  • LIST OF FIGURES

  • FIGURE 1. GLOBAL SURGICAL HEMOSTATS MARKET SEGMENTATION
  • FIGURE 2. GLOBAL SURGICAL HEMOSTATS MARKET
  • FIGURE 3. SEGMENTATION SURGICAL HEMOSTATS MARKET
  • FIGURE 4. TOP INVESTMENT POCKET IN SURGICAL HEMOSTATS MARKET
  • FIGURE 5. MODERATE BARGAINING POWER OF BUYERS
  • FIGURE 6. MODERATE BARGAINING POWER OF SUPPLIERS
  • FIGURE 7. MODERATE THREAT OF NEW ENTRANTS
  • FIGURE 8. LOW THREAT OF SUBSTITUTION
  • FIGURE 9. HIGH COMPETITIVE RIVALRY
  • FIGURE 10. OPPORTUNITIES, RESTRAINTS AND DRIVERS: GLOBALSURGICAL HEMOSTATS MARKET
  • FIGURE 11. SURGICAL HEMOSTATS MARKET SEGMENTATION, BY BY PRODUCT TYPE
  • FIGURE 12. SURGICAL HEMOSTATS MARKET FOR GELATIN BASED, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 13. SURGICAL HEMOSTATS MARKET FOR COMBINATION HEMOSTATS, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 14. SURGICAL HEMOSTATS MARKET FOR CELLULOSE BASED, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 15. SURGICAL HEMOSTATS MARKET FOR OXIDIZED REGENERATED, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 16. SURGICAL HEMOSTATS MARKET FOR COLLAGEN BASED, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 17. SURGICAL HEMOSTATS MARKET SEGMENTATION, BY BY END USERS
  • FIGURE 18. SURGICAL HEMOSTATS MARKET FOR HOSPITALS, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 19. SURGICAL HEMOSTATS MARKET FOR AMBULATORY SURGICAL CENTERS, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 20. SURGICAL HEMOSTATS MARKET FOR SPECIALTY CLINICS, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 21. TOP WINNING STRATEGIES, BY YEAR, 2022-2024*
  • FIGURE 22. TOP WINNING STRATEGIES, BY DEVELOPMENT, 2022-2024*
  • FIGURE 23. TOP WINNING STRATEGIES, BY COMPANY, 2022-2024*
  • FIGURE 24. PRODUCT MAPPING OF TOP 10 PLAYERS
  • FIGURE 25. COMPETITIVE DASHBOARD
  • FIGURE 26. COMPETITIVE HEATMAP: SURGICAL HEMOSTATS MARKET
  • FIGURE 27. TOP PLAYER POSITIONING, 2024
  • FIGURE 28. CSL BEHRING: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 29. CSL BEHRING: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 30. CSL BEHRING: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 31. JOHNSON AND JOHNSON: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 32. JOHNSON AND JOHNSON: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 33. JOHNSON AND JOHNSON: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 34. MARINE POLYMER TECHNOLOGIES, INC.: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 35. MARINE POLYMER TECHNOLOGIES, INC.: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 36. MARINE POLYMER TECHNOLOGIES, INC.: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 37. CRYOLIFE, INC.: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 38. CRYOLIFE, INC.: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 39. CRYOLIFE, INC.: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 40. C. R. BARD, INC.: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 41. C. R. BARD, INC.: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 42. C. R. BARD, INC.: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 43. Z-MEDICA, LLC: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 44. Z-MEDICA, LLC: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 45. Z-MEDICA, LLC: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 46. BAXTER, PFIZER INC.: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 47. BAXTER, PFIZER INC.: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 48. BAXTER, PFIZER INC.: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 49. INTEGRA LIFESCIENCES HOLDINGS CORPORATION: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 50. INTEGRA LIFESCIENCES HOLDINGS CORPORATION: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 51. INTEGRA LIFESCIENCES HOLDINGS CORPORATION: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 52. B BRAUN MELSUNGEN AG: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 53. B BRAUN MELSUNGEN AG: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 54. B BRAUN MELSUNGEN AG: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 55. VASCULAR SOLUTIONS, INC.: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 56. VASCULAR SOLUTIONS, INC.: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 57. VASCULAR SOLUTIONS, INC.: REVENUE SHARE, BY REGION, 2024 (%)

Purchase Full Report of
Surgical Hemostats Market

PURCHASE OPTIONS



* Taxes/Fees, If applicable will be added during checkout. All prices in USD.

Have a question ?

Need to add more ?

Avail up to 30% discount on subscription plans on


Avenue

© 2025 Allied Market Research. All Rights Reserved